$16.880
+0.132 (+0.78%)收盤時
CARL 資訊
CARL 事件
Carlsmed Files $250M Mixed Securities Shelf
Carlsmed files $250M mixed securities shelf
Q2 Revenue of $18.94M Exceeds Expectations
Reports Q2 revenue $18.94M, consensus $17.95M. "Our second quarter 2026 results reflect the growing momentum of aprevo procedures and further progress on our path to profitability," said Mike Cordonnier, Chairman and Chief Executive Officer. "We delivered 57% revenue growth year-over-year, expanded gross margins by 340 basis points, and grew our trained surgeon user base by more than 60% over the prior year. We continue to see strong volume growth across lumbar and cervical aprevo procedures, with continued advancements in our proprietary digital production system enabling scalability ahead of strong market demand. We believe the recent CMS ruling - which takes effect on October 1, 2026, and provides new and enhanced hospital reimbursement for the aprevo lumbar procedure - positions us well for ongoing growth in the years to come."
Company Expects 2026 Revenue to Reach $74.83M
Consensus $74.83M. The company said, "Revenue for the full year 2026 is expected to be in the range of $74 to $78 million, representing growth of over 50% at the midpoint of the range over 2025. This compares to prior guidance of $72 to $77 million."
Carlsmed Secures Favorable Reimbursement Policy from CMS
Carlsmed announced that the Centers for Medicare & Medicaid Services, or CMS, has finalized a favorable reimbursement policy applicable to inpatient aprevo Lumbar spinal fusion procedures in the Hospital Inpatient Prospective Payment System, or IPPS, Final Rule for FY27. The new MS-DRG assignments and payment rates will go into effect on October 1. In the FY27 IPPS Final Rule, CMS addressed Carlsmed's request and reassigned aprevo Lumbar fusion procedures to three newly created MS-DRGs 523, 524, and 525. Under the final rule, all inpatient aprevo Lumbar fusion procedures are eligible for reimbursement under one of these three new MS-DRG codes.
Carlsmed Q1 Revenue $16.12M Beats Expectations
Reports Q1 revenue $16.12M, consensus $14.98M. "We began 2026 with strong momentum, delivering 58% year-over-year revenue growth, publishing meaningful clinical data, and debuting new products to continue to advance our mission of improved patient outcomes and reduced cost of healthcare," said Mike Cordonnier, Chairman and Chief Executive Officer of Carlsmed. "The publication of peer-reviewed data from a retrospective cohort study in Global Spine Journal demonstrates a 74% reduction in revision rates for aprevo, which represents one of the most significant advancements in reducing reoperations in adult spinal deformity over the past two decades. With our first full commercial quarter for aprevo Cervical and the anticipated launch of our corra patient-specific fixation portfolio later this year, we believe we are well positioned for continued growth and innovation throughout 2026."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。